Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Analysts

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) have been given an average recommendation of “Buy” by the seventeen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $77.20.

A number of research firms have recently commented on XENE. Deutsche Bank Aktiengesellschaft raised their price objective on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. JPMorgan Chase & Co. raised their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Royal Bank Of Canada raised their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Guggenheim restated a “buy” rating and issued a $90.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, March 9th.

Xenon Pharmaceuticals Price Performance

Xenon Pharmaceuticals stock opened at $55.58 on Thursday. The stock’s 50-day moving average is $54.76 and its 200-day moving average is $49.53. The company has a market cap of $5.37 billion, a price-to-earnings ratio of -11.83 and a beta of 0.62. Xenon Pharmaceuticals has a 12 month low of $30.00 and a 12 month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the company earned ($0.83) earnings per share. Research analysts anticipate that Xenon Pharmaceuticals will post -4.92 EPS for the current year.

Insider Transactions at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director directly owned 1,455 shares in the company, valued at $77,318.70. This trade represents a 44.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.07% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several hedge funds have recently modified their holdings of XENE. Danske Bank A S purchased a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter valued at about $32,000. Blue Trust Inc. raised its holdings in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 717 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at about $33,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter valued at about $39,000. Finally, Osaic Holdings Inc. raised its holdings in shares of Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,034 shares during the period. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.